- Home
- SOR vs ANNX Comparison
SOR vs ANNX Comparison
Compare SOR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- ANNX
- Stock Information
- Founded
- SOR 1968
- ANNX 2011
- Country
- SOR United States
- ANNX United States
- Employees
- SOR N/A
- ANNX N/A
- Industry
- SOR Investment Managers
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- ANNX Health Care
- Exchange
- SOR Nasdaq
- ANNX Nasdaq
- Market Cap
- SOR 368.0M
- ANNX 334.1M
- IPO Year
- SOR N/A
- ANNX 2020
- Fundamental
- Price
- SOR $45.87
- ANNX $3.17
- Analyst Decision
- SOR
- ANNX Strong Buy
- Analyst Count
- SOR 0
- ANNX 4
- Target Price
- SOR N/A
- ANNX $13.00
- AVG Volume (30 Days)
- SOR 16.2K
- ANNX 1.9M
- Earning Date
- SOR 01-01-0001
- ANNX 11-14-2025
- Dividend Yield
- SOR 7.24%
- ANNX N/A
- EPS Growth
- SOR N/A
- ANNX N/A
- EPS
- SOR 6.50
- ANNX N/A
- Revenue
- SOR N/A
- ANNX N/A
- Revenue This Year
- SOR N/A
- ANNX N/A
- Revenue Next Year
- SOR N/A
- ANNX N/A
- P/E Ratio
- SOR $6.41
- ANNX N/A
- Revenue Growth
- SOR N/A
- ANNX N/A
- 52 Week Low
- SOR $36.41
- ANNX $1.29
- 52 Week High
- SOR $42.75
- ANNX $7.63
- Technical
- Relative Strength Index (RSI)
- SOR 60.74
- ANNX 53.03
- Support Level
- SOR $44.99
- ANNX $2.89
- Resistance Level
- SOR $46.00
- ANNX $3.60
- Average True Range (ATR)
- SOR 0.64
- ANNX 0.25
- MACD
- SOR 0.01
- ANNX -0.03
- Stochastic Oscillator
- SOR 88.50
- ANNX 39.86
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.